Pfizer to pay $24M settlement in copay kickback case

Pfizer gave more than $10 million to a charity for heart patients while dramatically increasing the price of one of its antiarrhythmic drugs, deflecting costs from patients and leaving Medicare with a bigger bill, the U.S. Justice Department said in a May 24 settlement statement.

The pharmaceutical company was ordered to pay $23.85 million to settle the kickback charges. According to Bloomberg, Pfizer said the settlement isn’t an admission of liability and none of its executives have been disciplined.

Pfizer raised the price of Tikosyn by 44 percent during the last three months of 2015, the same year it gave more than $10 million to the Patient Access Network Foundation. These charities are supposed to operate independently from industry donors, but the Justice Department said patients taking Tikosyn accounted for most of the beneficiaries in the first nine months after the fund opened.

Read more below:

""

Daniel joined TriMed’s Chicago editorial team in 2017 as a Cardiovascular Business writer. He previously worked as a writer for daily newspapers in North Dakota and Indiana.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.